Scarica l'app Stockscreener
4.935
0.51%
-0.015
Precedente Chiudi:
$4.92
Aprire:
$4.9
Volume 24 ore:
1.81M
Relative Volume:
0.48
Capitalizzazione di mercato:
$482.58M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
-1.90%
1M Prestazione:
-14.27%
6M Prestazione:
+13.31%
1 anno Prestazione:
+160.37%
Intervallo 1D:
$4.82
$4.99
Intervallo di 1 settimana:
$4.58
$5.027
Portata 52W:
$1.67
$7.2904
Atyr Pharma Inc Stock (ATYR) Company Profile
Nome
Atyr Pharma Inc
Settore
Industria
Telefono
(858) 731-8389
Indirizzo
10240 SORRENTO VALLEY ROAD, SAN DIEGO
Confronta ATYR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ATYR
Atyr Pharma Inc
|
4.925 | 481.11M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
398.93 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
600.04 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
463.81 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
662.30 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.92 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Atyr Pharma Inc Stock (ATYR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-18 | Iniziato | Leerink Partners | Outperform |
| 2025-01-06 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-10-04 | Iniziato | Wells Fargo | Overweight |
| 2024-09-05 | Iniziato | Jefferies | Buy |
| 2023-07-05 | Downgrade | Oppenheimer | Outperform → Perform |
| 2021-10-12 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-09-21 | Iniziato | Piper Sandler | Overweight |
| 2021-05-10 | Iniziato | Laidlaw | Buy |
| 2020-08-17 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2020-03-04 | Iniziato | ROTH Capital | Buy |
| 2020-03-02 | Iniziato | Oppenheimer | Outperform |
| 2018-02-14 | Downgrade | JP Morgan | Neutral → Underweight |
| 2017-09-07 | Iniziato | Piper Jaffray | Overweight |
| 2016-12-13 | Downgrade | JP Morgan | Overweight → Neutral |
| 2015-12-16 | Iniziato | Citigroup | Neutral |
| 2015-06-01 | Iniziato | Citigroup | Buy |
| 2015-06-01 | Iniziato | JP Morgan | Overweight |
Mostra tutto
Atyr Pharma Inc Borsa (ATYR) Ultime notizie
What institutional flow reveals about aTyr Pharma Inc.Long Setup & Weekly High Return Stock Opportunities - Newser
How to track smart money flows in aTyr Pharma Inc.Weekly Profit Summary & Risk Managed Investment Entry Signals - Newser
Is it too late to sell aTyr Pharma Inc.Risk Management & Real-Time Buy Signal Alerts - Newser
How to use a screener to detect aTyr Pharma Inc. breakoutsQuarterly Earnings Report & Technical Entry and Exit Alerts - Newser
Moving Average Crossover Confirms Uptrend in aTyr Pharma Inc.2025 Bull vs Bear & Stepwise Trade Execution Plans - beatles.ru
aTyr Pharma Inc.’s volatility index tracking explainedJuly 2025 Pullbacks & Weekly Chart Analysis and Guides - Newser
ATyr Pharma Rated as Overweight at Cantor Fitzgerald on Efzofitimod Expectations - Yahoo Finance
Live market analysis of aTyr Pharma Inc.Gold Moves & Free Safe Capital Growth Stock Tips - Newser
Is aTyr Pharma Inc. stock bottoming outBreakout Watch & Free Growth Oriented Trading Recommendations - Newser
Analyzing drawdowns of aTyr Pharma Inc. with statistical tools2025 Valuation Update & Real-Time Stock Movement Alerts - Newser
What makes aTyr Pharma Inc. stock price move sharplyNew Guidance & High Return Stock Watch Alerts - beatles.ru
Technical analysis overview for aTyr Pharma Inc. stockQuarterly Profit Review & AI Based Buy and Sell Signals - Newser
Developing predictive dashboards with aTyr Pharma Inc. dataEarnings Risk Summary & Real-Time Price Movement Reports - Newser
High Growth US Tech Stocks To Watch In August 2025 - Yahoo Finance
RSI Crosses Above 30 for aTyr Pharma Inc. — Reversal in SightTrade Analysis Summary & Daily Stock Trend Reports - beatles.ru
Regression analysis insights on aTyr Pharma Inc. performanceEarnings Risk Report & AI Driven Stock Reports - Newser
aTyr Pharma: Estimating Their Phase 3 Lung Disease Trial Outcome (NASDAQ:ATYR) - Seeking Alpha
Does aTyr Pharma Inc. qualify in momentum factor screeningMarket Activity Summary & Weekly High Return Stock Forecasts - Newser
Risk adjusted return profile for aTyr Pharma Inc. analyzed2025 Key Lessons & Breakout Confirmation Alerts - Newser
Heatmap analysis for aTyr Pharma Inc. and competitorsWeekly Trade Review & Verified Short-Term Plans - Newser
Is aTyr Pharma Inc. a play on infrastructure spendingDividend Hike & Daily Growth Stock Tips - newsimpact.co.kr
Applying Elliott Wave Theory to aTyr Pharma Inc.Weekly Gains Report & Risk Adjusted Buy/Sell Alerts - Newser
How to escape a deep drawdown in aTyr Pharma Inc.2025 Year in Review & Short-Term Trading Opportunity Alerts - Newser
Can machine learning forecast aTyr Pharma Inc. recoveryIndex Update & AI Forecasted Entry and Exit Points - Newser
Is aTyr Pharma Inc. exposed to currency risksTrend Reversal & AI Enhanced Trade Execution Alerts - thegnnews.com
XTX Topco Ltd Has $59,000 Stock Holdings in aTyr Pharma, Inc. (NASDAQ:ATYR) - Defense World
Trendlines Suggest aTyr Pharma Inc. May Bottom Out SoonTechnical Breakout Signal Plan Strategy - beatles.ru
Optimistic Outlook for aTyr Pharma Amidst Controversies: Analyst Highlights Potential in EFZO-FIT Study - TipRanks
Custom Dashboard Highlights aTyr Pharma Inc. Price MomentumEarnings Miss & Free Growth Oriented Trading Recommendations - sundaytimes.kr
aTyr Pharma Inc. Shows Support at Fibonacci LevelJuly 2025 EndofMonth & Fast Moving Market Watchlists - newsyoung.net
Published on: 2025-08-14 00:58:46 - Newser
Analysts Offer Insights on Healthcare Companies: PepGen Inc. (PEPG), Cullinan Management (CGEM) and aTyr Pharma (ATYR) - The Globe and Mail
Will aTyr Pharma Inc. Bounce From 52 Week LowPotential Breakout Stock List Published This Week - sundaytimes.kr
ATYR.O Plummets 7.8%: A Deep Dive into the Unusual Intraday Move - AInvest
aTyr Pharma Inc. Outperforms Peers on Volume MetricsSwing Setup With Technical Confirmation Explained - 선데이타임즈
Optimistic Buy Rating for aTyr Pharma Amid Promising Phase 3 Data and Innovative Sarcoidosis Treatment Approach - TipRanks
aTyr Pharma, Inc. (NASDAQ:ATYR) Given Consensus Rating of “Buy” by Brokerages - Defense World
aTyr Pharma Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Traders Consider Averaging Down in aTyr Pharma Inc.Entry Alert Based on Volume Spikes Detected - metal.it
Promising Developments and Strong Financial Position Drive Buy Rating for aTyr Pharma - TipRanks
1 Small-Cap Biotech Stock Poised for a Breakout - AOL.com
Connect Biopharma Holdings Limited shares rise 1.93% intraday after aTyr Pharma announced Phase 3 EFZO-FIT™ study completion. - AInvest
aTyr Pharma Inc expected to post a loss of 16 cents a shareEarnings Preview - TradingView
3 Innovation Stocks With Parabolic Upside Potential - AOL.com
Atyr Pharma: Q2 Earnings Snapshot - Connecticut Post
aTyr Pharma Reports Q2 2025 Financial Results - TipRanks
aTyr Pharma Announces Second Quarter 2025 Results and Provides Corporate Update - GlobeNewswire
aTyr Pharma reports Q2 EPS (22c), consensus (18c) - TipRanks
ATYR Stock: A Comprehensive Analysis and Forecast - investchronicle.com
Atyr Pharma Inc Azioni (ATYR) Dati Finanziari
Non sono disponibili dati finanziari per Atyr Pharma Inc (ATYR). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
Atyr Pharma Inc Azioni (ATYR) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Broadfoot Jill Marie | Chief Financial Officer |
Feb 04 '25 |
Sale |
3.78 |
1,254 |
4,740 |
31,763 |
| DENYES NANCY | General Counsel |
Feb 04 '25 |
Sale |
3.78 |
899 |
3,398 |
26,555 |
1.33%
0.64%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):